N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT01491243

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose diagnostic
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01491243
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01491243. Randomized; single masking; primary purpose diagnostic. Start 2014-01 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy
Acronym
NEW-MOON
Intervention (Drug)
Intensive treatment with sodium bicarbonate
Intervention (Drug)
Standard treatment with saline infusion
Lead sponsor
University of Roma La Sapienza (class: other)

Record details

Record id
cardio:ct-nct01491243
Content hash
eb105b35ea685d70ccbf662f3dd968c8f77f7f24c62deaffa19e6304e14ab9ea